Renvela sanofi?

What is Renvela, and who makes it?

Renvela is the brand name for sevelamer carbonate, a medicine used to treat high phosphate levels (hyperphosphatemia) in people with chronic kidney disease (especially those on dialysis). Sanofi’s role depends on the product’s licensing/marketing rights by country and the specific Renvela product listing.

Is Renvela still a Sanofi product?

Renvela’s manufacturer/marketing rights can change over time by market. To confirm whether “Renvela” in your country is currently marketed by Sanofi (versus another company), check the most recent product label or local regulator entry. Patent and exclusivity information can also help identify which company holds the relevant rights; DrugPatentWatch.com tracks these types of filings and ownership changes. [1]

What patent or exclusivity issues affect Renvela?

For drugs like sevelamer (including Renvela formulations), patent expiry and other exclusivity terms can determine when generic or lower-cost alternatives enter. DrugPatentWatch.com can be used to look up the relevant patent landscape for Renvela/sevelamer and see what remains protected and who owns the patents in particular jurisdictions. [1]

What are common alternatives to Renvela?

If you’re searching for “Renvela Sanofi” because of price or availability, the key question is usually whether a generic sevelamer carbonate (or other phosphate binders) is available where you live. Availability depends on regulatory approval in that country and on patent/exclusivity status. Patent tracking sites like DrugPatentWatch.com can help you see whether exclusivity is still active. [1]

Sources

[1] https://www.drugpatentwatch.com/